Urticaria

Dermatology
3
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Faes Farma
Faes FarmaSpain - Leioa
1 program
1
BilastinePhase 31 trial
Active Trials
NCT00421109Completed522Est. Jul 2007
UP
UCB PharmaBelgium - Brussels
1 program
1
levocetirizine dihydrochloridePhase 31 trial
Active Trials
NCT00525382Completed134Est. Mar 2004
Genentech
GenentechCA - Oceanside
1 program
1
RituximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00216762Terminated15Est. May 2007
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Alesion®N/A1 trial
Active Trials
NCT02238249Completed122
Novartis
NovartisBASEL, Switzerland
1 program
Basophil patternsN/A1 trial
Active Trials
NCT02671006Completed60Est. Aug 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Faes FarmaBilastine
UCB Pharmalevocetirizine dihydrochloride
GenentechRituximab
NovartisBasophil patterns
Boehringer IngelheimAlesion®

Clinical Trials (5)

Total enrollment: 853 patients across 5 trials

NCT00421109Faes FarmaBilastine

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Start: Jul 2006Est. completion: Jul 2007522 patients
Phase 3Completed
NCT00525382UCB Pharmalevocetirizine dihydrochloride

Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria

Start: Aug 2003Est. completion: Mar 2004134 patients
Phase 3Completed
NCT00216762GenentechRituximab

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

Start: Jan 2006Est. completion: May 200715 patients
Phase 1/2Terminated
NCT02671006NovartisBasophil patterns

Monitoring Chronic Urticaria Basophil Irritability by Cytometry

Start: Mar 2016Est. completion: Aug 201760 patients
N/ACompleted
NCT02238249Boehringer IngelheimAlesion®

Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria

Start: Oct 2005122 patients
N/ACompleted

Related Jobs in Dermatology

MSL/Senior MSL, Dermatology - Tampa, Florida

AbbVie
Remote
6h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
6h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
6h ago

Regional Sales Trainer - Dermatology (Central / West Regions)

AbbVie
Remote
7h ago

Regional Sales Trainer - Dermatology (Northeast / Southeast Regions)

AbbVie
Remote
7h ago

Delegado Especialista Ventas Dermatología (Inmunología)

AbbVie
Remote
11h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Dermatitis, Atopic(42)Hidradenitis Suppurativa(30)Chronic Spontaneous Urticaria(21)Alopecia Areata(17)Hidradenitis Suppurativa (HS)(10)Vitiligo(9)Rosacea(6)Chronic Urticaria(5)Pruritus(5)Androgenetic Alopecia(5)